News Headlines

  1. Nanoform Starts Pivotal Human Bioequivalence Studies Of Nanoenzalutamide 6/12/2025

    Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started pivotal relative bioequivalence studies of Nanoenzalutamide, the nanocrystalline-enabled enzalutamide tablet formulation, a potential alternative to the amorphous solid dispersion (ASD) used in XTANDI® (enzalutamide) [1], the number one prescribed androgen receptor inhibitor [2] approved to treat prostate cancer.

  2. Simtra BioPharma Solutions And MilliporeSigma Announce Strategic Alliance For Antibody Drug Conjugates Drug Substance And Drug Product Manufacturing Services 6/12/2025
  3. UCB Announces Major U.S. Investment To Expand Biologics Manufacturing Capacity 6/12/2025

    UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States.

  4. BioNTech Announces Strategic Transaction To Acquire CureVac In Public Exchange Offer 6/12/2025

    BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”).

  5. TekniPlex Healthcare Opens New Flagship Barrier Protection Systems Facility In Madison, Wisconsin 6/12/2025

    TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, has commenced production activities at its new 200,000-square-foot facility in Madison, Wisconsin.

  6. MaxCyte And Ori Biotech Collaborate To Improve Manufacturing Efficiencies And Broaden Adoption Of Autologous Cellular Therapies 6/11/2025

    MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing.

  7. Cytiva Completing 1.6 Billion USD In Strategic Investments To Further Enhance Global Supply Chain And Customer Benefits 6/11/2025

    Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in several locations in the United States, Europe, and Asia as part of its ongoing commitment to enhancing delivery for customers developing and manufacturing advanced therapeutics.

  8. ClavystBio And A*STAR Partner To Grow MedTech Ventures In Singapore 6/10/2025

    ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore.

  9. XL-Protein Grants Worldwide License To Grifols To Develop A Biopharmaceutical Using PASylation® Technology 6/10/2025

    XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, for a novel, long-acting biopharmaceutical product.

  10. Echosens And Boehringer Ingelheim Expand Long-Standing Collaboration To Accelerate Progress In MASH Diagnosis And Care 6/10/2025

    As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in non-invasive liver diagnostics, and Boehringer Ingelheim, a global biopharmaceutical company, today announced an expansion of their long-standing partnership to change the trajectory of the disease by moving beyond clinical trials to focus on early detection, diagnosis, and access to care.